Citius Pharmaceuticals, Inc. (CTXR): Operating Cash Flow
-$26.55M
Year ended 2025-09-30
-$34.87M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | -$26.55M | n/m | 2025-12-23, From 2024-10-01 |
| 2024-09-30 | -$28.20M | n/m | 2025-12-23, From 2023-10-01 |
| 2023-09-30 | -$29.06M | n/m | 2024-12-27, From 2022-10-01 |
| 2022-09-30 | -$28.36M | n/m | 2023-12-29, From 2021-10-01 |
| 2021-09-30 | -$24.25M | n/m | 2022-12-22, From 2020-10-01 |
| 2020-09-30 | -$16.93M | n/m | 2021-12-15, From 2019-10-01 |
| 2019-09-30 | -$12.44M | n/m | 2020-12-16, From 2018-10-01 |
| 2018-09-30 | -$11.32M | n/m | 2019-12-16, From 2017-10-01 |
| 2017-09-30 | -$7.97M | n/m | 2019-12-16, From 2016-10-01 |
| 2016-09-30 | -$5.90M | n/m | 2018-12-11, From 2015-10-01 |
| 2015-09-30 | -$2.39M | n/m | 2017-12-13, From 2014-10-01 |
| 2014-09-30 | -$183.2K | n/m | 2016-12-23, From 2013-10-01 |
| 2013-09-30 | -$20.6K | n/m | 2014-02-06, From 2012-10-01 |
| 2012-09-30 | -$20.3K | n/m | 2014-02-06, From 2011-10-01 |
| 2011-09-30 | -$20.8K | n/a | 2013-01-15, From 2010-10-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | -$26.55M | n/m |
| Silence Therapeutics plc (SLN) | 2025-12-31 | -$62.27M | n/m |
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | -$63.66M | n/m |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | -$17.65M | n/m |
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $1.12M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $23.75M | +218.5% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | -$12.20M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$56.30M | n/m |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | -$4.77M | n/m |
Compare CTXR, SLN, ACRV, ZOMDF side by side · Screen every company in Pharmaceutical Preparations ↗